Posterior reversible encephalopathy syndrome (PRES) in classic Hodgkin's lymphoma, complicated by anthracycline-induced cardiomyopathy

BMJ Case Rep. 2024 Aug 14;17(8):e257523. doi: 10.1136/bcr-2023-257523.

Abstract

A woman in her 20s with no medical history was diagnosed with bulky stage II classic Hodgkin's lymphoma after an 8-week history of shortness of breath, cough and lethargy. A regimen of doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) was commenced with six cycles planned. During the first cycle, the patient was profoundly hypertensive. She then suffered two self-terminating tonic-clonic seizures.Examination and investigations diagnosed posterior reversible encephalopathy syndrome (PRES), which resolved completely in 11 days with strict blood pressure control and withholding chemotherapy. Treatment was further complicated by anthracycline-induced cardiomyopathy, requiring a switch in regimen to gemcitabine BVD.The patient made a full recovery from neurology and cardiology perspectives and completed six cycles of chemotherapy, achieving a complete metabolic response by the tumour. We illustrate the case, describe differential diagnoses and management of PRES, its association with chemotherapy and the successful chemotherapy rechallenge.

Keywords: Cancer intervention; Drugs: CNS (not psychiatric); Epilepsy and seizures; Haematology (incl blood transfusion); Oncology.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anthracyclines / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols* / adverse effects
  • Bleomycin* / adverse effects
  • Cardiomyopathies* / chemically induced
  • Cardiomyopathies* / diagnosis
  • Dacarbazine* / adverse effects
  • Diagnosis, Differential
  • Doxorubicin* / adverse effects
  • Female
  • Gemcitabine
  • Hodgkin Disease* / drug therapy
  • Humans
  • Magnetic Resonance Imaging
  • Posterior Leukoencephalopathy Syndrome* / chemically induced
  • Posterior Leukoencephalopathy Syndrome* / diagnosis
  • Vinblastine* / adverse effects
  • Vinblastine* / therapeutic use

Substances

  • Doxorubicin
  • Dacarbazine
  • Bleomycin
  • Vinblastine
  • Anthracyclines
  • Gemcitabine

Supplementary concepts

  • ABVD protocol